Dr Jenni Gunter
Position:
- Research Fellow, Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute, Queensland University of Technology
Websites:
Biography:
Dr Gunter is an early career researcher at the Australian Prostate Cancer Research Centre-Queensland. She has a strong metabolic research background spanning almost 10 years. She completed her PhD at Oxford University examining the effect of obesity on beta cell function and type 2 diabetes, and has published peer reviewed articles and a book chapter on metabolic dysregulation related to obesity.
Dr Gunter has presented her findings at local and international conferences. She was awarded a University of Queensland Postdoctoral Fellowship in 2006 and returned to Australia to pursue studies into the turnover and metabolism of adipocytes in obesity. Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
Best publications:
- Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC. The interactions between insulin and androgens in progression to castrate resistant prostate cancer. Advances in Urology, vol. 2012, Article ID 248607, 11 pages, 2012. doi:10.1155/2012/248607
- Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Research 2011 Sep1:71)17):5754-64.
- Gunter JH, Sarkar P, Lubik AA, Nelson CC. New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. (Accepted at International Journal of Cell Biology)
- Lubik AA, Gunter JH, Hollier BG, Fazli L, Ettinger S, Stylianou N, Adomat H, Hendy SC, Gleave M, Pollak MN, Herington A, Nelson CC. Insulin-like growth factor-2 increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer. 2013 Jan 14. [Epub ahead of print; ]
- Moffitt JH, Fielding BA, Evershed R, Berstan R, Currie JM, Clark A. Adverse physicochemical properties of tripalmitin in beta cells lead to morphological changes and lipotoxicity in vitro. Diabetologia 2005 Sep; 48(9):1819-29.
cancer progression, castrate resistance, exogenous factors, gene regulation, metabolic syndrome, metastases.
